{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:49:39Z","timestamp":1781304579278,"version":"3.54.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008728","name":"Japan Research Foundation for Clinical Pharmacology","doi-asserted-by":"publisher","award":["2018A10"],"award-info":[{"award-number":["2018A10"]}],"id":[{"id":"10.13039\/100008728","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18K06785"],"award-info":[{"award-number":["18K06785"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20H05798"],"award-info":[{"award-number":["20H05798"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ejphar.2022.175083","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T20:38:28Z","timestamp":1654029508000},"page":"175083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Investigation of drugs for the prevention of doxorubicin-induced cardiac events using big data analysis"],"prefix":"10.1016","volume":"928","author":[{"given":"Shiori","family":"Nishiuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0869-5786","authenticated-orcid":false,"given":"Kenta","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroumi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Zamami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Niimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshika","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiko","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuka","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5345-1479","authenticated-orcid":false,"given":"Mitsuhiro","family":"Goda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Chuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Izawa-Ishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Nawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Yanagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunari","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2022.175083_bib1","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1126\/science.281.5381.1322","article-title":"The Bcl-2 protein family: arbiters of cell survival","volume":"281","author":"Adams","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2022.175083_bib2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ahj.2004.08.005","article-title":"Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)","volume":"149","author":"Adams","year":"2005","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ejphar.2022.175083_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.taap.2014.01.013","article-title":"Glucocorticoid induced leucine zipper inhibits apoptosis of cardiomyocytes by doxorubicin","volume":"276","author":"Aguilar","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175083_bib4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2022.175083_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2353\/ajpath.2008.070974","article-title":"Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling","volume":"173","author":"Bujak","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2022.175083_bib6","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/cncr.33974","article-title":"Late health outcomes after dexrazoxane treatment: a report from the Children's Oncology Group","volume":"128","author":"Chow","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.ejphar.2022.175083_bib7","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s00204-016-1759-y","article-title":"Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone","volume":"90","author":"Damiani","year":"2016","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.ejphar.2022.175083_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/npjsba.2016.15","article-title":"L1000CDS2: LINCS L1000 characteristic direction signatures search engine","volume":"2","author":"Duan","year":"2016","journal-title":"NPJ Syst. Biol. Appl."},{"key":"10.1016\/j.ejphar.2022.175083_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/nar\/30.1.207","article-title":"Gene Expression Omnibus: NCBI gene expression and hybridization array data repository","volume":"30","author":"Edgar","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2022.175083_bib10","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","article-title":"Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy","volume":"342","author":"Felker","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2022.175083_bib11","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/1078155220965674","article-title":"Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: a network meta-analysis of metastatic breast cancer","volume":"27","author":"Ghasemi","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.ejphar.2022.175083_bib12","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/CIRCRESAHA.117.311335","article-title":"Quaking inhibits doxorubicin-mediated cardiotoxicity through regulation of cardiac circular RNA expression","volume":"122","author":"Gupta","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2022.175083_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/HJH.0000000000001898","article-title":"Development of a novel aortic dissection mouse model and evaluation of drug efficacy using in-vivo assays and database analyses","volume":"37","author":"Izawa-Ishizawa","year":"2019","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejphar.2022.175083_bib14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3390\/biom12020299","article-title":"RRM2 alleviates doxorubicin-induced cardiotoxicity through the AKT\/mTOR signaling pathway","volume":"12","author":"Jiao","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejphar.2022.175083_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cels.2017.11.001","article-title":"The library of integrated network-based cellular signatures NIH program: system-level cataloging of human cells response to perturbations","volume":"6","author":"Keenan","year":"2018","journal-title":"Cell Syst"},{"key":"10.1016\/j.ejphar.2022.175083_bib16","doi-asserted-by":"crossref","first-page":"6663","DOI":"10.18632\/oncotarget.16944","article-title":"Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity","volume":"8","author":"Koleini","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2022.175083_bib17","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1136\/heartjnl-2013-304449","article-title":"The effects of gender and age on occurrence of clinically suspected myocarditis in adulthood","volume":"99","author":"Kyt\u00f6","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.ejphar.2022.175083_bib18","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/pds.1601","article-title":"A comparison of measures of disproportionality for signal detection on adverse drug reaction spontaneous reporting database of Guangdong province in China","volume":"17","author":"Li","year":"2008","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ejphar.2022.175083_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ppedcard.2014.09.007","article-title":"Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: an update of the evidence","volume":"36","author":"Lipshultz","year":"2014","journal-title":"Prog. Pediatr. Cardiol."},{"key":"10.1016\/j.ejphar.2022.175083_bib20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline chemotherapy and cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ejphar.2022.175083_bib21","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tice.2017.03.007","article-title":"Protective role of CoQ10 or L-carnitine on the integrity of the myocardium in doxorubicin induced toxicity","volume":"49","author":"Mustafa","year":"2017","journal-title":"Tissue Cell"},{"key":"10.1016\/j.ejphar.2022.175083_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/srep26375","article-title":"Prevention of antipsychotic-induced hyperglycaemia by vitamin D: a data mining prediction followed by experimental exploration of the molecular mechanism","volume":"6","author":"Nagashima","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2022.175083_bib23","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/eurheartj\/ehl193","article-title":"EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population","volume":"27","author":"Nieminen","year":"2006","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2022.175083_bib24","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/cam4.1920","article-title":"Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database","volume":"8","author":"Okada","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.ejphar.2022.175083_bib25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0092-8674(93)90509-O","article-title":"Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death","volume":"74","author":"Oltvai","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2022.175083_bib26","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.2217\/fon-2018-0210","article-title":"Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling","volume":"14","author":"Reichardt","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejphar.2022.175083_bib27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/leu.2009.261","article-title":"Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984\u20132001: a report from the children's oncology group","volume":"24","author":"Salzer","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2022.175083_bib28","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2008-10-184143","article-title":"A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate-and high-risk Hodgkin lymphoma: the results of P9425","volume":"114","author":"Schwartz","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2022.175083_bib29","first-page":"406","article-title":"Anti-inflammatory and antioxidative effects of sumatriptan against doxorubicin-induced cardiotoxicity in rat","volume":"59","author":"Sheibani","year":"2021","journal-title":"Acta Med. Iran."},{"key":"10.1016\/j.ejphar.2022.175083_bib30","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00280-019-04019-6","article-title":"Cardioprotective effects of dapsone against doxorubicin-induced cardiotoxicity in rats","volume":"85","author":"Sheibani","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175083_bib31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.toxlet.2019.02.013","article-title":"Oxidative stress injury in doxorubicin-induced cardiotoxicity","volume":"307","author":"Songbo","year":"2019","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.ejphar.2022.175083_bib32","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","article-title":"Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer","volume":"15","author":"Swain","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2022.175083_bib33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","article-title":"Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems","volume":"65","author":"Tacar","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175083_bib34","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132747","article-title":"Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity","volume":"5","author":"Tadokoro","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejphar.2022.175083_bib35","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ehf2.12616","article-title":"Reactive fibrosis precedes doxorubicin-induced heart failure through sterile inflammation","volume":"7","author":"Tanaka","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejphar.2022.175083_bib36","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1200\/JCO.2005.02.3879","article-title":"Dexrazoxane-associated risk for acute myeloid leukemia\/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease","volume":"25","author":"Tebbi","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2022.175083_bib37","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0735-1097(97)00494-4","article-title":"Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure","volume":"31","author":"Tsutamoto","year":"1998","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2022.175083_bib38","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bbrc.2019.12.027","article-title":"Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes","volume":"523","author":"Yu","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2022.175083_bib39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.yjmcc.2017.10.008","article-title":"CTRP3 protected against doxorubicin-induced cardiac dysfunction, inflammation and cell death via activation of Sirt1","volume":"114","author":"Yuan","year":"2018","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ejphar.2022.175083_bib40","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.3389\/fphar.2019.01257","article-title":"Search for therapeutic agents for cardiac arrest using a drug discovery tool and large-scale medical information database","volume":"10","author":"Zamami","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175083_bib41","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2019.3113","article-title":"Factors associated with immune checkpoint inhibitor-related myocarditis","volume":"5","author":"Zamami","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejphar.2022.175083_bib42","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.redox.2017.12.013","article-title":"MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2","volume":"15","author":"Zhao","year":"2018","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejphar.2022.175083_bib43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.redox.2018.02.026","article-title":"Protective effect of dioscin against doxorubicin-induced cardiotoxicity via adjusting microRNA-140-5p-mediated myocardial oxidative stress","volume":"16","author":"Zhao","year":"2018","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejphar.2022.175083_bib44","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejphar.2010.06.024","article-title":"Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity","volume":"643","author":"Zhu","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175083_bib45","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.biopha.2011.06.005","article-title":"Interleukin-1 signaling mediates acute doxorubicin-induced cardiotoxicity","volume":"65","author":"Zhu","year":"2011","journal-title":"Biomed. Pharmacother."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922003442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922003442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:02:57Z","timestamp":1757977377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299922003442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":45,"alternative-id":["S0014299922003442"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175083","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation of drugs for the prevention of doxorubicin-induced cardiac events using big data analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"175083"}}